Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (OM) drives innovation in dialysis care through its groundbreaking Tablo Hemodialysis System. This page serves as the definitive source for verified news and press releases about the company’s advancements in medical technology, financial performance, and strategic initiatives.
Access real-time updates on product milestones, regulatory developments, and clinical partnerships that shape OM’s position in the healthcare sector. Investors and healthcare professionals will find comprehensive coverage of earnings reports, FDA clearances, and technology adoption trends across hospitals and home care settings.
Our curated news collection features:
• Product Innovations: Latest enhancements to the Tablo system’s integrated dialysis solutions
• Financial Updates: Quarterly earnings and strategic investment announcements
• Clinical Partnerships: Collaborations improving renal care delivery models
• Regulatory Milestones: FDA clearances and compliance developments
Bookmark this page for streamlined access to OM’s evolving role in transforming dialysis through technology that prioritizes patient outcomes and operational efficiency.
Outset Medical, Inc. reported its financial results for the first quarter of 2024, highlighting revenue of $28.2 million, a 12% growth in service and other revenue, and a total gross margin improvement to 29.2%. Operating expenses decreased by 10% from the prior year. The company remains focused on reducing costs, achieving profitability, and capitalizing on the $11 billion U.S. dialysis market opportunity.
Outset Medical, Inc. (Nasdaq: OM) received FDA 510(k) clearance for TabloCart with prefiltration, an accessory for the Tablo Hemodialysis System, improving flexibility for healthcare providers. This innovative technology enhances user experience with versatile prefiltration options and enhanced maneuverability, simplifying dialysis treatment. TabloCart complements Tablo as a single enterprise solution, revolutionizing the dialysis experience for patients and providers.
Outset Medical, a medical technology company (OM), will be presenting at upcoming investor conferences hosted by BofA Securities and RBC Capital Markets in May 2024. The management will discuss the company's innovative dialysis technology to reduce costs and complexity. Webcasts of the sessions will be available on Outset's investor section website.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
